EDIT

Editas Medicine Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 4/10
  • Value↓ 1/10
Editas Medicine sales and earnings growth
EDIT Growth
Neutral
  • Revenue Y/Y↑ 25.39%
  • EPS Y/Y↑ 37.50%
  • FCF Y/Y↑ 24.43%
Editas Medicine gross and profit margin trends
EDIT Profitability
Fair
  • Gross margin ↑ 100.00%
  • EPS margin↓ -395.00%
  • ROIC 5Y↓ -96.53%
Editas Medicine net debt vs free cash flow
EDIT Risk
Great
  • Debt / Equity↑ 2.8
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -75.8

Editas Medicine stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗